BCL2L11 and cancer: In contrast, ALK, BACH2, BCL2L11, BRAF, CYLT, DNMT1, IDH2, LEF1, MAP3K7, MYC, MTCN, SIRT1, TARDBP, TERT, TSC1, USP22, and FLT3 enhance the sensitivity of these drugs in cancers.